跳至主要内容
临床试验/IRCT20200304046696N1
IRCT20200304046696N1尚未招募3 期

Early Anti-Coagulation therapy in new onset atrial fibrillation after coronary artery bypass graft operation; Warfarin vs Rivaroxaban for stroke prevention and risk of bleeding assessment: A randomized clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 1,590 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
1,590

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Patients who undergone Isolated coronary artery bypass graft in Tehran Heart Center
  • Two or more episodes of New Onset Atrial Fibrillation (each lasting > 20 minutes) or persistent atrial fibrillation lasting > 24 hours

排除标准

  • History of allergy to study drugs
  • History of recent stroke (within 1 month) before surgery or post-operation before initiation of study medications
  • At least moderate Mitral or Aortic valve stenosis not repaired or replaced by surgery
  • Recent (within 1 year) or ongoing pregnancy (Blood pregnancy test (b-HCG level) will be checked for young women at the beginning of the study)
  • Any other indication for anticoagulation therapy (Including DVT, PTE, mechanical valve)
  • Baseline INR > 1.7
  • History of atrial fibrillation before operation
  • Postoperative bleeding before initiation of anticoagulation medications
  • Glomerular filtration rate(GFR) < 30 ml/min

研究者

相似试验

Early Anti-Coagulation therapy in new onset atrial... | 临床试验